Clinical trial · Observational
Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide
NCT06069024CI-TRIAL-00075841completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-intervention, prospective, open-label and observational clinical trial. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study was to establish a population pharmacokinetic(PPK) model of lenalidomide and explore factors associated with the adverse events of lenalidomide from a pharmacokinetic(PK) perspective.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- drug blood concentration
- timeFrame
- 2 years
- description
- Blood samples of patients who took lenalidomide were collected by opportunistic blood collection, which were used for concentration determination by using HPLC/MS. Lenalidomide blood levels in patients were prevalent between 1-1000 ng/ml.
- measure
- genotype
- timeFrame
- 1 month
- description
- Genotypes of patients needed to be determined include ABCB1 3435 C\>T, ABCB1 1236 A\>G and ABCB1 2677 A\>C/T.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are above the age of 18 * Patients who receive lenalidomide treatment Exclusion Criteria: * Patients have received other investigational systemic drugs * The clinical data are deemed insufficient * There appear other factors that rendered them ineligible.
References
Publications (0)
Data not yet available
No reference posted for this study.